rs372348401
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BS2
The NM_003738.5(PTCH2):c.626C>T(p.Pro209Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000106 in 1,610,896 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P209R) has been classified as Uncertain significance.
Frequency
Consequence
NM_003738.5 missense
Scores
Clinical Significance
Conservation
Publications
- nevoid basal cell carcinoma syndromeInheritance: AD, Unknown Classification: MODERATE, SUPPORTIVE, LIMITED Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- commissural facial cleftInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -4 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PTCH2 | ENST00000372192.4 | c.626C>T | p.Pro209Leu | missense_variant | Exon 6 of 22 | 1 | NM_003738.5 | ENSP00000361266.3 | ||
| PTCH2 | ENST00000447098.7 | c.626C>T | p.Pro209Leu | missense_variant | Exon 6 of 23 | 1 | ENSP00000389703.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152164Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.0000323 AC: 8AN: 247758 AF XY: 0.0000297 show subpopulations
GnomAD4 exome AF: 0.0000110 AC: 16AN: 1458732Hom.: 0 Cov.: 31 AF XY: 0.00000827 AC XY: 6AN XY: 725546 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152164Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74336 show subpopulations
ClinVar
Submissions by phenotype
not specified Uncertain:1
The c.626C>T (p.P209L) alteration is located in exon 6 (coding exon 6) of the PTCH2 gene. This alteration results from a C to T substitution at nucleotide position 626, causing the proline (P) at amino acid position 209 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Gorlin syndrome Uncertain:1
This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 209 of the PTCH2 protein (p.Pro209Leu). This variant is present in population databases (rs372348401, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PTCH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1354511). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PTCH2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at